NASDAQ:CPRXCatalyst Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $4.05 -0.09 (-2.17 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$3.95Now: $4.05▼$4.2050-Day Range$4.13MA: $4.70▼$5.0852-Week Range$2.55Now: $4.05▼$7.67Volume2.71 million shsAverage Volume1.45 million shsMarket Capitalization$418.89 millionP/E Ratio10.13Dividend YieldN/ABeta1.86 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCatalyst Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.20, Catalyst Pharmaceuticals has a potential upside of 127.2% from its current price of $4.05.Amount of Analyst CoverageCatalyst Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesCatalyst Pharmaceuticals has received 432 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCatalyst Pharmaceuticals has received 283 “underperform” votes. (Add your “underperform” vote.)Community SentimentCatalyst Pharmaceuticals has received 60.42% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Catalyst Pharmaceuticals and other stocks. Vote “Outperform” if you believe CPRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CPRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCatalyst Pharmaceuticals does not currently pay a dividend.Dividend GrowthCatalyst Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Catalyst Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.70% of the stock of Catalyst Pharmaceuticals is held by insiders.Percentage Held by Institutions63.68% of the stock of Catalyst Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Catalyst Pharmaceuticals are expected to grow by 28.95% in the coming year, from $0.38 to $0.49 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Catalyst Pharmaceuticals is 10.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 17.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Catalyst Pharmaceuticals is 10.13, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.Price to Book Value per Share RatioCatalyst Pharmaceuticals has a P/B Ratio of 4.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.00 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CPRX Previous Symbol CUSIPN/A CIK1369568 Webwww.catalystpharma.com Phone305-420-3200Debt Debt-to-Equity Ratio0.01 Current Ratio6.63 Quick Ratio6.51Price-To-Earnings Trailing P/E Ratio10.13 Forward P/E Ratio10.66 P/E GrowthN/A Sales & Book Value Annual Sales$102.31 million Price / Sales4.09 Cash Flow$0.30 per share Price / Cash Flow13.28 Book Value$0.85 per share Price / Book4.76Profitability EPS (Most Recent Fiscal Year)$0.30 Net Income$31.88 million Net Margins36.09% Return on Equity52.28% Return on Assets42.40%Miscellaneous Employees51 Outstanding Shares103,430,000Market Cap$418.89 million Next Earnings Date8/10/2020 (Confirmed) OptionableOptionable $4.05 -0.09 (-2.17 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CPRX News and Ratings via Email Sign-up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Catalyst Pharmaceuticals (NASDAQ:CPRX) Frequently Asked Questions How has Catalyst Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Catalyst Pharmaceuticals' stock was trading at $3.52 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CPRX shares have increased by 15.1% and is now trading at $4.05. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Catalyst Pharmaceuticals? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalyst Pharmaceuticals. When is Catalyst Pharmaceuticals' next earnings date? Catalyst Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Catalyst Pharmaceuticals. How can I listen to Catalyst Pharmaceuticals' earnings call? Catalyst Pharmaceuticals will be holding an earnings conference call on Monday, August 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available. How were Catalyst Pharmaceuticals' earnings last quarter? Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) released its earnings results on Monday, May, 11th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.09 by $0.01. The biopharmaceutical company had revenue of $29.14 million for the quarter, compared to the consensus estimate of $31.68 million. Catalyst Pharmaceuticals had a net margin of 36.09% and a return on equity of 52.28%. View Catalyst Pharmaceuticals' earnings history. What price target have analysts set for CPRX? 5 Wall Street analysts have issued 1-year target prices for Catalyst Pharmaceuticals' stock. Their forecasts range from $7.00 to $12.00. On average, they anticipate Catalyst Pharmaceuticals' share price to reach $9.20 in the next year. This suggests a possible upside of 127.2% from the stock's current price. View analysts' price targets for Catalyst Pharmaceuticals. Has Catalyst Pharmaceuticals been receiving favorable news coverage? Media headlines about CPRX stock have been trending very positive on Saturday, InfoTrie reports. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Catalyst Pharmaceuticals earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Catalyst Pharmaceuticals. Who are some of Catalyst Pharmaceuticals' key competitors? Some companies that are related to Catalyst Pharmaceuticals include I-Mab (IMAB), Corcept Therapeutics (CORT), Ironwood Pharmaceuticals (IRWD), INDIVIOR PLC/S (INVVY), Eidos Therapeutics (EIDX), Madrigal Pharmaceuticals (MDGL), IGM Biosciences (IGMS), Y-mAbs Therapeutics (YMAB), Intercept Pharmaceuticals (ICPT), MacroGenics (MGNX), Dicerna Pharmaceuticals (DRNA), Rocket Pharmaceuticals (RCKT), Akebia Therapeutics (AKBA), Zymeworks (ZYME) and Portola Pharmaceuticals (PTLA). View all competitors. What other stocks do shareholders of Catalyst Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), Sorrento Therapeutics (SRNE), AcelRx Pharmaceuticals (ACRX), SCYNEXIS (SCYX) and Micron Technology (MU). Who are Catalyst Pharmaceuticals' key executives? Catalyst Pharmaceuticals' management team includes the following people: Mr. Patrick J. McEnany, Co-Founder, Chairman, Pres & CEO (Age 72)Ms. Alicia Grande, VP, Treasurer & CFO (Age 48)Dr. Steven R. Miller, COO & Chief Scientific Officer (Age 57)Mr. Brian Elsbernd, Chief Legal & Compliance Officer (Age 55)Dr. Gary Ingenito, Chief Medical Officer & Head of Regulatory Affairs (Age 63) What is Catalyst Pharmaceuticals' stock symbol? Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX." Who are Catalyst Pharmaceuticals' major shareholders? Catalyst Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Gables Capital Management Inc. (0.49%), Cadence Capital Management LLC (0.32%), Hancock Whitney Corp (0.31%), Russell Investments Group Ltd. (0.30%), Raymond James Financial Services Advisors Inc. (0.24%) and Swiss National Bank (0.21%). Company insiders that own Catalyst Pharmaceuticals stock include Charles B O'keeffe, Donald A Denkhaus, Gary Ingenito and Patrick J Mcenany. View institutional ownership trends for Catalyst Pharmaceuticals. Which institutional investors are selling Catalyst Pharmaceuticals stock? CPRX stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Leap Investments LP, Strs Ohio, Russell Investments Group Ltd., and Gables Capital Management Inc.. View insider buying and selling activity for Catalyst Pharmaceuticals. Which institutional investors are buying Catalyst Pharmaceuticals stock? CPRX stock was acquired by a variety of institutional investors in the last quarter, including Hancock Whitney Corp, LSV Asset Management, Wedge Capital Management L L P NC, Rafferty Asset Management LLC, Seizert Capital Partners LLC, XML Financial LLC, Swiss National Bank, and Creative Planning. Company insiders that have bought Catalyst Pharmaceuticals stock in the last two years include Charles B O'keeffe, Donald A Denkhaus, and Patrick J Mcenany. View insider buying and selling activity for Catalyst Pharmaceuticals. How do I buy shares of Catalyst Pharmaceuticals? Shares of CPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Catalyst Pharmaceuticals' stock price today? One share of CPRX stock can currently be purchased for approximately $4.05. How big of a company is Catalyst Pharmaceuticals? Catalyst Pharmaceuticals has a market capitalization of $418.89 million and generates $102.31 million in revenue each year. The biopharmaceutical company earns $31.88 million in net income (profit) each year or $0.30 on an earnings per share basis. Catalyst Pharmaceuticals employs 51 workers across the globe. What is Catalyst Pharmaceuticals' official website? The official website for Catalyst Pharmaceuticals is www.catalystpharma.com. How can I contact Catalyst Pharmaceuticals? Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The biopharmaceutical company can be reached via phone at 305-420-3200 or via email at [email protected] This page was last updated on 8/8/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
